Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rilertinib
- Development stage
- Phase 3
- Lead developer
- Nanjing Sanhome Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Rilertinib is an orally administered, pyrimidine-based irreversible epidermal growth factor receptor (EGFR) antagonist developed by Nanjing Sanhome Pharmaceutical. It targets specific EGFR mutations including T790M, exon 19 deletion, and exon 21 L858R mutation. Rilertinib is classified as a small molecule antineoplastic agent and has reached registration status for the treatment of non-small cell lung cancer (NSCLC), where it has demonstrated superior progression-free survival compared to gefitinib in patients with EGFR-mutated NSCLC[2][4][7]. Its mechanism involves irreversible inhibition of mutant EGFR signaling pathways that drive tumor growth.
- Brand names
- Sanrisso
- Other names
- rilertinib mesylateoritnib
02
Targets
Beyond the preview
Go deeper on rilertinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rilertinib.